Home / Products / STAAR Surgical

STAAR Surgical

ICL (Implantable Collamer Lens) for high myopia and astigmatism correction - reversible implant that preserves the cornea

Product Brochure

đź“Ą Download Brochure (PDF)

Product Video

STAAR Surgical EVO

STAAR Surgical manufactures the EVO ICL™ family of Implantable Collamer® Lenses.

STAAR Surgical is a world-leading American company in ophthalmic implant technologies since 1991. ICL is a reversible and safe refractive surgery solution that corrects from low to high levels of refractive errors without touching the corneal tissue. It is a phakic intraocular implant, placed directly behind the iris and in front of the natural crystalline lens, that can treat a wide range of refractive errors. It is a premium, minimally invasive solution that is added to the eye without removing corneal tissue. It has a proven track record of over 30 years, with more than 3 million ICL lenses distributed worldwide.

Collamer Material

Unique Biocompatible Material

Collamer® is a proprietary premium material exclusive to STAAR Surgical. Collamer is derived from two words that describe its composition: “Collagen” and “Copolymer”. It is a copolymer of poly-HEMA and collagen that offers UV protection. Collamer minimizes inflammation, flare, and cellular reaction [Schild G ,et al. - Brown DC, Ziemba SL]

Schild G, Amon M, Abela-Formanek C, Schauersberger J, Bartl G, Kruger A. Uveal and capsular biocompatibility of a single-piece, sharp-edged hydrophilic acrylic intraocular lens with collagen (Collamer®): 1-year results. J Cataract Refract Surg 2004;30(6):1254-8.

Brown DC, Ziemba SL. Collamer® intraocular lens: clinical results from the US FDA core study. J Cataract Refract Surg. 2001;27(6):833-40.

Biocompatible: Perfect compatibility inside the eye

UV Protection: Collamer is copolymer with a UV absorbing chromophore that offers UV protection; can block 90% of UV light at 387 nm.

Flexible: Foldable structure

Transparent: Optically clear

Permanent: Implanted lenses have been shown to remain in the eye for >10 years without deterioration of the surface or optical properties.

Advantages:

  • âś“ Minimal inflammation risk
  • âś“ Long-term stability
  • âś“ Compatible with natural lens

ICL Product Family

EVO Visian ICL

With CentraFLOW Technology

EVO ICL is the new generation ICL that does not require pre-operative iridotomy thanks to its central port (CentraFLOW).

CentraFLOW Advantages:

  • âś“ No iridotomy needed
  • âś“ Rapid visual recovery
  • âś“ Reduces incidence of anterior sub-capsular cataract and pupillary block versus earlier models
  • âś“ Natural aqueous flow

Technical Features:

  • Central port diameter: 360 microns
  • KS-AquaPORT® technology

EVO+ Visian ICL

Extended Correction Range

EVO+ is EVO with expanded optical zone

Features:

  • All advantages of EVO technology
  • EVO+ spherical power range: -0.5 D to -14.0 D
  • Optimized optical design

Correction Range:

  • Myopia: -0.50 D to -20.0 D
  • Ideal for high myopia

Toric ICL (For Astigmatism)

Myopia + Astigmatism Correction

Toric ICL is a specially designed ICL that corrects both myopia and astigmatism.

Features:

  • Cylinder power: 0.5 D to 6.0 D
  • Rotational stability
  • Horizontal marking
  • Myopia + astigmatism combined

Versions:

  • EVO Visian Toric ICL (with CentraFLOW)
  • EVO+ Visian Toric ICL

Correction:

  • Spherical: -0.5 D to -18.0 D
  • Cylindrical: 0.5 D to 6.0 D

ICL Indications

Primary Indications

Age

  • EVO Candidates may include patients aged 21 to 60 years old with a stable refraction.

High Myopia

  • EVO candidates may include patients unsuitable for laser vision correction (LVC) or who don’t want LVC, within the indicated correction range.

Moderate-High Astigmatism

  • 1.0 D - 6.0 D cylindrical
  • Irregular astigmatism
  • Residual post-LASIK

Thin Cornea

  • Also suitable for patients with thin corneas.

Dry Eye

  • EVO ICL™ doesn’t cause or worsen dry eye

ICL Advantages

Cornea Preserved:

  • âś“ No corneal tissue removal
  • âś“ Preserves the cornea and crystalline lens.
  • âś“ Does not induce dry eye syndrome.
    1. Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017;11:1253-1263.

Reversible:

  • âś“ Lens removable
  • âś“ Exchangeable
  • âś“ Upgradeable

Wide Correction:

  • âś“ -0.5 D to -20.0 D (with ACD ≥ 2.8 mm)
  • âś“ Up to 6.0 D astigmatism
  • âś“ Suitable for thin cornea
  • âś“ Suitable for steep cornea

Vision Quality:

  • âś“ Excellent night vision.

Other Advantages

Fast Recovery:

  • Rapid visual recovery
  • Minimal pain
  • Quick return to work

UV Protection:

  • Offers UV protection

Long-term Safety:

  • Low rate of adverse events.
  • EVO has 10 year follow up:
    1. Alfonso-Bartolozzi B, Fernández-Vega-Cueto L, Lisa C, Palacios A, Madrid-Costa D, Alfonso JF. Ten-Year Follow-up of Posterior Chamber Phakic Intraocular Lens with Central Port Design in patients with low- and normal-vault. J Cataract Refract Surg. Published online December 12, 2023.

Aesthetic:

  • Invisible from outside
  • Natural appearance
  • Glasses-free life

ICL Results

Patient Satisfaction

Satisfaction Rate:

  • Exceptional Patient Satisfaction - high rate of the patients surveyed say they would have the procedure again.
  1. Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clinical ophthalmology (Auckland, NZ). 2018;12:2427-38

Gem Engineering Services

Product Supply

STAAR Surgical ICL Products:

  • EVO Visian ICL
  • EVO+ Visian ICL
  • Toric ICL (all versions)
  • Complete product range

Services:

  • Fast order processing
  • Ready stock
  • Cold chain logistics
  • Original product guarantee

Training and Certification

Surgical Training:

  • STAAR-approved training program
  • Hands-on workshop
  • Live surgery observation
  • Proctored cases (first cases)

Calculation Training:

  • ICL calculator usage
  • Vault optimization
  • Lens selection
  • Complication management

Technical Support

Preoperative:

  • Patient selection consultation
  • ICL calculation support
  • Lens size recommendation

Intraoperative:

  • Surgical technique consultation
  • 24/7 emergency support line

Postoperative:

  • Complication management
  • Exchange cases
  • Follow-up protocols

Marketing Support

Patient Materials:

  • Brochures (English & Turkish)
  • Video content
  • Before/after images
  • Social media content

Clinic Materials:

  • Waiting room posters
  • Digital screen content
  • Website integration
  • SEO-supported content

Clinical Studies and Approvals

Regulatory Approvals

  • âś“ FDA Approved (USA)
  • âś“ CE Marked (Europe)
  • âś“ TFDA Approved (Turkey)
  • âś“ Approved in 75+ countries

Clinical Data

Implanted Lenses:

  • Worldwide 3,000,000+ lenses distributed
  • Used in 60+ countries

Scientific Publications:

  • Proven Clinical Outcomes: The ICL technology is backed by over 1,000 peer-reviewed publications. The latest model, EVO ICL, has more than 500 published studies, with 300+ focusing on clinical outcomes—some with up to 10 years of follow-up.

For more information

Web Site: STAAR Surgical Website - Directions For Use

Gem Engineering is the distributor of STAAR Surgical products in Turkey. All products are original and guaranteed. STAAR Surgical certification is required for ICL surgery.

Note: This content is for informational purposes. ICL implantation should only be performed by certified surgeons.

Important Safety Information for the EVO/EVO+ ICL

  • All physicians must complete the STAAR Surgical Visian ICL Physician Training Certification Program prior to using the EVO/EVO+ ICL in a clinical setting. Please review the EVO/EVO+ ICL Directions For Use (DFU) completely before performing a clinical procedure. INDICATIONS: The EVO/EVO+ ICL is indicated for phakic patients 21-60 years and pseudophakic patients 21 years and older with an anterior chamber depth (ACD) 2.8 mm or greater to correct/reduce myopia ranging from -0.5 diopters to -20.0 diopters with up to 6.0 D of astigmatism. The EVO/EVO+ ICL is intended for placement in the posterior chamber of the eye. WARNING/PRECAUTION: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/ benefit ratio before implanting a lens in a patient with any of the conditions described in the DFU. Prior to surgery, physicians should inform prospective patients of possible risks and benefits associated with the EVO/EVO+ ICL. ATTENTION: Reference the EVO/EVO+ ICL DFU available at https://edfu.staar.com/edfu/ for a complete listing of indications, contraindications, warnings and precautions.